Articles related to TARGETED THERAPIES

Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.

A gynecologic oncologist reviews the current role of immune checkpoint inhibition across locally advanced and recurrent cervical cancer settings, including KEYNOTE-A18 survival data, key regulatory distinctions, and unanswered sequencing questions.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.